Olympus Corporation (TYO:7733)
Japan flag Japan · Delayed Price · Currency is JPY
1,729.50
+6.50 (0.38%)
Jul 24, 2026, 3:30 PM JST

Revenue by Geography

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
Japan Revenue
103.91B110.53B
North America Revenue
405.49B413.90B
Europe Revenue
281.07B254.62B
China Revenue
82.45B95.74B
Asia and Oceania Revenue (Post-FY2019 Reporting)
102.59B93.71B
Asia and Oceania Revenue (Pre-FY2020 Reporting)
185.04B189.45B
Other Countries Revenue
35.17B28.84B

Revenue Breakdown

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
Gastrointestinal Solutions Division Revenue
697.36B674.04B
Surgical & Interventional Solutions Division Revenue
313.11B322.76B

Revenue Breakdown 2

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
Endoscopic Solutions Division Revenue
636.14B
Therapeutic Solutions Division Revenue
360.66B
Total Medical Solutions Division Revenue
996.80B
Other Division Revenue (Post-FY2024 Reporting)
530.00M

EBIT

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
Gastrointestinal Solutions Division Operating Profit
136.36B171.44B
Surgical & Interventional Solutions Division Operating Profit
-14.99B15.27B

EBIT 2

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
Endoscopic Solutions Division Operating Profit
141.40B
Therapeutic Solutions Division Operating Profit
61.45B
Total Medical Solutions Division Operating Profit
202.85B
Other Division Operating Profit (Post-FY2024 Reporting)
-473.00M
Eliminations from Division Operating Profit
-39.92B

Key Performance Indicators

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
ESD - GI Endoscopy Revenue Growth Rate After FX Adjustment
-3.00%
ESD - Surgical Endoscopy Revenue Growth Rate After FX Adjustment
-5.00%
ESD - Medical Service Revenue Growth Rate After FX Adjustment
-5.00%
Total Endoscopic Solutions Division (ESD) Revenue Growth Rate After FX Adjustment
-4.00%
TSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment
-2.00%
TSD - Urology Revenue Growth Rate After FX Adjustment
-6.00%
TSD - Respiratory Revenue Growth Rate After FX Adjustment
-10.00%
TSD - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment
--7.00%
Total Therapeutic Solutions Division (TSD) Revenue Growth Rate After FX Adjustment
-3.00%
GSD - GI Endoscopy Revenue Growth Rate After FX Adjustment
1.00%-
GSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment
4.00%-
GSD - Medical Service Revenue Growth Rate After FX Adjustment
3.00%-
Total Gastrointestinal Solutions Division Revenue Growth Rate After FX Adjustment
2.00%-
SIS - Respiratory Revenue Growth Rate After FX Adjustment
1.00%-
SIS - Surgical Endoscopy Revenue Growth Rate After FX Adjustment
-6.00%-
SIS - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment
-15.00%-
Total Surgical & Interventional Solutions Division Revenue Growth Rate After FX Adjustment
-4.00%-